Literature DB >> 26492428

Multisession Radiosurgery for Sellar and Parasellar Benign Meningiomas: Long-term Tumor Growth Control and Visual Outcome.

Marcello Marchetti1, Stefania Bianchi, Valentina Pinzi, Irene Tramacere, Maria Luisa Fumagalli, Ida Maddalena Milanesi, Paolo Ferroli, Angelo Franzini, Marco Saini, Francesco DiMeco, Laura Fariselli.   

Abstract

BACKGROUND: Concern about radiation-induced optic neuropathy (RION) has governed recent thinking about the role of radiation therapy in the treatment of meningiomas involving the anterior optic pathways. Despite this concern, during the last few years, the use of radiosurgery for such lesions has increased steadily.
OBJECTIVE: To define both the tumor control rate and the risk of RION over a long-term follow-up period in a large cohort of patients treated with multisession radiosurgery.
METHODS: The local control and visual outcome of 143 patients who underwent multisession radiosurgery (mRS) were evaluated. Neurological outcome was also analyzed. The data for the present study were obtained from a prospectively maintained database.
RESULTS: The mean follow-up was 44 months (range, 12-113 months). All patients underwent mRS. The median prescription dose was 25 Gy delivered in 3 to 5 fractions. The prescription isodose, which typically encompassed at least 95% of the tumor, ranged from 65% to 86% (median, 80%). The mean tumor volume was 11.0 cm (range, 0.1-126.3 cm; median, 8 cm). The progression-free survival at 3, 5, and 8 years was 100%, 93%, and 90%, respectively. Compared with baseline, visual function improved in 36% of patients, whereas 7.4% experienced a worsening in visual function (5.1% excluding the patients with progressive disease).
CONCLUSION: Good local control rate and a low risk of RION indicate that mRS is a safe and effective treatment option in cases of large meningiomas.

Entities:  

Mesh:

Year:  2016        PMID: 26492428     DOI: 10.1227/NEU.0000000000001073

Source DB:  PubMed          Journal:  Neurosurgery        ISSN: 0148-396X            Impact factor:   4.654


  13 in total

1.  Radiosurgical decompression for benign perioptic tumors causing compressive cranial neuropathies: a feasible alternative to microsurgery?

Authors:  Eun Jung Lee; Young Hyun Cho; KyoungJun Yoon; Byungchul Cho; Eun Suk Park; Chang Jin Kim; Sung Woo Roh
Journal:  J Neurooncol       Date:  2016-09-06       Impact factor: 4.130

Review 2.  Single session versus multisession stereotactic radiosurgery for the management of intracranial meningiomas: a systematic review and meta-analysis.

Authors:  Othman Bin-Alamer; Nada Alnefaie; Jumanah Qedair; Adhiraj Chaudhary; Hana Hallak; Arif Abdulbaki; Arka N Mallela; Paolo Palmisciano; Zachary C Gersey; Andrew D Legarreta; Mohamed A Labib; Gabriel Zada; Jason P Sheehan; William T Couldwell; L Dade Lunsford; Hussam Abou-Al-Shaar
Journal:  J Neurooncol       Date:  2022-08-17       Impact factor: 4.506

Review 3.  Hypofractionated stereotactic radiotherapy for intracranial meningioma: a systematic review.

Authors:  Eric K Nguyen; Timothy K Nguyen; Gabe Boldt; Alexander V Louie; Glenn S Bauman
Journal:  Neurooncol Pract       Date:  2018-12-20

Review 4.  Single- and Multi-Fraction Stereotactic Radiosurgery Dose Tolerances of the Optic Pathways.

Authors:  Michael T Milano; Jimm Grimm; Scott G Soltys; Ellen Yorke; Vitali Moiseenko; Wolfgang A Tomé; Arjun Sahgal; Jinyu Xue; Lijun Ma; Timothy D Solberg; John P Kirkpatrick; Louis S Constine; John C Flickinger; Lawrence B Marks; Issam El Naqa
Journal:  Int J Radiat Oncol Biol Phys       Date:  2018-01-31       Impact factor: 8.013

5.  Neuro-ophthalmologic outcomes of standard versus hypo-fractionated stereotactic radiotherapy of AVPM.

Authors:  Leor Zach; Amir Agami; Orit Furman; Moshe Attia; Zvi Cohen; Iris Ben-Bassat Mizrachi; Guy Tam; Zion Zibly; Ouzi Nissim; Roberto Spiegelmann; Ruth Huna-Baron
Journal:  Radiat Oncol       Date:  2021-08-28       Impact factor: 3.481

6.  Surgical management of anterior clinoidal meningiomas: consensus statement on behalf of the EANS skull base section.

Authors:  D Starnoni; C Tuleasca; L Giammattei; G Cossu; M Bruneau; M Berhouma; J F Cornelius; L Cavallo; S Froelich; E Jouanneau; T R Meling; D Paraskevopoulos; H Schroeder; M Tatagiba; I Zazpe; A Sufianov; M E Sughrue; Ari G Chacko; V Benes; P González-Lopez; Pierre-Hugues Roche; Marc Levivier; Mahmoud Messerer; Roy T Daniel
Journal:  Acta Neurochir (Wien)       Date:  2021-08-16       Impact factor: 2.216

Review 7.  Advances in Multidisciplinary Management of Skull Base Meningiomas.

Authors:  Tamara Ius; Alessandro Tel; Giuseppe Minniti; Teresa Somma; Domenico Solari; Michele Longhi; Pasquale De Bonis; Alba Scerrati; Mario Caccese; Valeria Barresi; Alba Fiorentino; Leonardo Gorgoglione; Giuseppe Lombardi; Massimo Robiony
Journal:  Cancers (Basel)       Date:  2021-05-28       Impact factor: 6.639

8.  Normofractionated stereotactic radiotherapy versus CyberKnife-based hypofractionation in skull base meningioma: a German and Italian pooled cohort analysis.

Authors:  Conti Alfredo; Senger Carolin; Acker Güliz; Kluge Anne; Pontoriero Antonio; Cacciola Alberto; Pergolizzi Stefano; Germanò Antonino; Badakhshi Harun; Kufeld Markus; Meinert Franziska; Nguyen Phuong; Loebel Franziska; Vajkoczy Peter; Budach Volker; Kaul David
Journal:  Radiat Oncol       Date:  2019-11-12       Impact factor: 3.481

9.  Radiation-induced cavernous malformation after stereotactic radiosurgery for cavernous sinus meningioma: a case report.

Authors:  Zuan Yu; Bin Huang; Risheng Liang
Journal:  BMC Neurol       Date:  2020-11-20       Impact factor: 2.474

10.  Stereotactic Radiosurgery for Intracranial Noncavernous Sinus Benign Meningioma: International Stereotactic Radiosurgery Society Systematic Review, Meta-Analysis and Practice Guideline.

Authors:  Marcello Marchetti; Arjun Sahgal; Antonio A F De Salles; Marc Levivier; Lijun Ma; Ian Paddick; Bruce E Pollock; Jean Regis; Jason Sheehan; John H Suh; Shoji Yomo; Laura Fariselli
Journal:  Neurosurgery       Date:  2020-10-15       Impact factor: 4.654

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.